Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes
WFMZ-TV 69,
CAMBRIDGE, Mass., Jan. 19, 2021 /PRNewswire/ --., a developer of novel cancer therapeutics, today announced that the first…